JPH0621074B2 - Lipid metabolism improver - Google Patents
Lipid metabolism improverInfo
- Publication number
- JPH0621074B2 JPH0621074B2 JP6895388A JP6895388A JPH0621074B2 JP H0621074 B2 JPH0621074 B2 JP H0621074B2 JP 6895388 A JP6895388 A JP 6895388A JP 6895388 A JP6895388 A JP 6895388A JP H0621074 B2 JPH0621074 B2 JP H0621074B2
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol
- lipid metabolism
- lipid
- present
- triglyceride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000037356 lipid metabolism Effects 0.000 title claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- FYGDTMLNYKFZSV-ANKSBSNASA-N alpha-D-Gal-(1->4)-beta-D-Gal-(1->4)-D-Glc Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-ANKSBSNASA-N 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 3
- 239000003524 antilipemic agent Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 3
- 229960000903 pantethine Drugs 0.000 description 3
- 235000008975 pantethine Nutrition 0.000 description 3
- 239000011581 pantethine Substances 0.000 description 3
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 3
- 229960003912 probucol Drugs 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229930194190 pantocin Natural products 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
【発明の詳細な説明】 ［産業上の利用分野］ 本発明は人間に対して著効である、 式 を有するＯ−β−Ｄ−ガラクトピラノシル−（１→４）
−Ｏ−β−Ｄ−ガラクトピラノシル−（１→４）−Ｄ−
グルコースで示される４′−ガラクトシルラクトース
（４′−ＧＬ）を有効成分とする脂質代謝改善剤に関す
る。DETAILED DESCRIPTION OF THE INVENTION [Industrial field of application] The present invention has a remarkable effect on humans. O-β-D-galactopyranosyl- (1 → 4) having
-O-β-D-galactopyranosyl- (1 → 4) -D-
The present invention relates to a lipid metabolism improving agent containing 4'-galactosyl lactose (4'-GL) represented by glucose as an active ingredient.
［従来の技術及び問題点］ 脂質代謝異常は、動脈硬化の進展、促進と重要な因果関
係が指摘され、コレステロール、トリグリセライド、遊
離脂肪酸などの脂質の異常を是正するような薬物が望ま
れている。その結果、各種の脂質低下剤が開発されてい
るが、これらの薬物は副作用も示し、使用に制限があっ
た。[Prior Art and Problems] It has been pointed out that lipid metabolism abnormality has an important causal relationship with the progress and promotion of arteriosclerosis, and drugs that correct lipid abnormalities such as cholesterol, triglyceride, and free fatty acids are desired. . As a result, various lipid lowering agents have been developed, but these drugs have side effects and their use is limited.
血中コレステロールを左右する因子、トリグリセライド
値を左右する因子は多岐にわたり、しかも血中脂質のう
ち、コレステロールとトリグリセライドでは生体内での
代謝に差があることが知られている。よって脂質低下剤
の作用機序も複雑であり、コレステロール、トリグリセ
ライドの代謝のいずれかの部分に作用して、両方のある
いは一方のみの脂質を低下させる場合もある。また、動
物の種類によっても、作用が異なり効果に差異が生じた
りする。臨床結果も動物実験とは異なる場合があった。It is known that there are various factors that affect blood cholesterol and triglyceride levels, and that among blood lipids, cholesterol and triglyceride have different metabolisms in vivo. Therefore, the action mechanism of the lipid lowering agent is also complicated, and it may act on any part of the metabolism of cholesterol or triglyceride to lower both or only one lipid. In addition, the action differs depending on the type of animal, and the effect may differ. The clinical results may also differ from the animal experiments.
高脂血症ラットを用いた動物試験で、食物繊維やある種
の難消化性糖類が効果があると指摘され、この４′−Ｇ
Ｌについてもセルロースとの併用で、成熟ＳＨＲの血圧
上昇、血漿総コレステロール量の減少した報告（第４１
回 日本栄養・食糧学会総会講演要旨集、昭和６２年、
１１８頁）もあるが人に対する臨床効果は明らかにされ
ていなかった。In animal tests using hyperlipidemic rats, it was pointed out that dietary fiber and certain indigestible sugars were effective.
Regarding L, the combined use of cellulose and L increased the blood pressure of mature SHR and decreased total plasma cholesterol (41st report).
Annual Meeting of Japan Society of Nutrition and Food Science, 1987,
(P. 118), but clinical effects on humans have not been clarified.
［発明が解決しようとする課題］ 本発明は、このような現状に鑑み発明されたもので、人
間に対して、副作用もなく、常時摂取することにより、
コレステロール量及びトリグリセライドを減少させ、Ｈ
ＤＬ−コレステロールを増加させることにより、脂質改
善を容易ならしめる物質を提供することにある。[Problems to be Solved by the Invention] The present invention has been invented in view of such a situation as described above.
Reduces cholesterol and triglyceride
The object is to provide a substance that facilitates lipid improvement by increasing DL-cholesterol.
［問題点を解決するための手段］ ４′−ＧＬを有効成分とする糖混合物を常時摂取するこ
とにより、人間の体内の脂質代謝改善に著効があること
を見い出し本発明に至った。[Means for Solving the Problems] The present invention was found to be extremely effective in improving lipid metabolism in the human body by constantly ingesting a sugar mixture containing 4'-GL as an active ingredient, and the present invention was completed.
本発明に用いる４′−ＧＬは特開昭６０−２５１８９６
号、特開昭６１−２３６７９０号、特開昭６１−２７１
９９９号、特開昭６１−２８９８５６号、特開昭６２−
１３０６９５号などに示されている方法で製造されるも
のを用いることができる。The 4'-GL used in the present invention is disclosed in JP-A-60-251896.
JP-A-61-236790, JP-A-61-271
999, JP 61-289856, JP 62-
Those manufactured by the method shown in No. 130695 can be used.
本発明の脂質代謝改善剤は４′−ＧＬを有効成分とする
ものであり、他の糖質・蛋白質・ミネラル等を含有した
混合物であっても良い。The lipid metabolism improving agent of the present invention contains 4'-GL as an active ingredient, and may be a mixture containing other carbohydrates, proteins, minerals and the like.
又他の脂質低下剤、一般名パンテチン、プロブコールな
どと併用することによって脂質改善効果はそれぞれ単独
よりもより効果は大きくなる。１日当りの使用量として
は、個人差や体重差もあり、特定することは難しいが、
１ｇから４０ｇ好ましくは３ｇ〜２０ｇである。これら
は、数回に分けて用いることもできる。４′−ＧＬの使
用方法としては特に制限はないが、経口適用が望まし
い。他の食品と混ぜて用いても良い。When used in combination with other lipid lowering agents, generic names pantethine, probucol, etc., the lipid-improving effect is greater than that of each. It is difficult to specify the daily usage amount due to individual differences and weight differences, but
It is 1 g to 40 g, preferably 3 to 20 g. These can also be used by dividing into several times. There is no particular limitation on the method of using 4'-GL, but oral application is preferable. You may mix and use it with other foods.
［発明の効果］ 本発明の４′−ＧＬは脂質改善剤として脂質代謝異常に
より数多くの成人病が発生している現代において、人間
の健康維持において極めて有用である。[Effects of the Invention] 4'-GL of the present invention is extremely useful as a lipid improving agent in the maintenance of human health in the present age when many adult diseases occur due to abnormal lipid metabolism.
［実施例］ 以下、本発明を実施例に基づき説明する。[Examples] Hereinafter, the present invention will be described based on Examples.
実施例１ 本実施例では、骨折後リハビリ中である８１歳の女性を
対象者とし、純度９５％の４′−ＧＬ、８ｇを単独で、
毎日１回温湯に溶解し服用した。Example 1 In this example, an 81-year-old woman undergoing rehabilitation after a fracture was targeted, and 4 g of 95% pure 4′-GL, 8 g alone,
It was dissolved in hot water once a day and taken.
その結果、投与後１ヶ月目には総コレステロールの顕著
な低下がみられ、トリグリセライド値も若干低下した。
一方、ＨＤＬ−コレステロールは投与後１ヶ月で増加
し、第１図に示すように順調な改善効果がみられた。As a result, the total cholesterol was remarkably reduced one month after the administration, and the triglyceride level was also slightly reduced.
On the other hand, HDL-cholesterol increased one month after administration, and as shown in FIG. 1, a favorable improving effect was observed.
実施例２ 本実施例では、脳梗塞後リハビリ中である８０歳の女性
を対象者とし、純度９５％の４′−ＧＬ、８ｇを単独
で、毎日１回温湯に溶解し服用した。Example 2 In this example, a 80-year-old woman undergoing rehabilitation after cerebral infarction was targeted, and 8 g of 4'-GL having a purity of 95% was dissolved in hot water once a day and was taken.
その結果、投与後、総コレステロール、トリグリセライ
ドは順調に減少し、ＨＤＬ−コレステロールは若干増加
し、第２図に示すように改善効果がみられた。投与をや
めると、効果は消失し投与前と同じ値になった。As a result, after administration, total cholesterol and triglyceride decreased steadily, and HDL-cholesterol slightly increased, showing an improving effect as shown in FIG. When the administration was stopped, the effect disappeared and the value was the same as before the administration.
実施例３ 本実施例は、４′−ＧＬとシンレスタール及びパントシ
ンの併用効果を示すものである。Example 3 This example shows the combined effect of 4'-GL with synrestal and pantocin.
長期臥床患者である４６歳男性を対象者とした。この対
象者には、プロブコール錠剤２錠パンテチン錠剤(200m
g)３錠を長期投与したいたが、脂質改善効果は認められ
なかった。The subject was a 46-year-old man who was a long-term bed rest patient. This subject had 2 probucol tablets and 200 pantethine tablets (200m
g) 3 tablets were administered for a long period of time, but no lipid improving effect was observed.
そこでこの対象者に、純度９５％の４′−ＧＬ、８ｇ
と、プロブコール錠剤２錠パンテチン錠剤(200mg)３錠
を併用投与したところ、第３図に示すように総コレステ
ロール、トリグリセライド、ＨＤＬ−コレステロールと
も４′−ＧＬとの併用投与により順調に改善した。Therefore, to this subject, 8 g of 4'-GL with a purity of 95% was added.
When 2 tablets of probucol and 3 tablets of pantethine (200 mg) were co-administered, total cholesterol, triglyceride, and HDL-cholesterol were improved steadily by coadministration with 4'-GL as shown in FIG.
投与をやめると、総コレステロール、ＨＤＬ−コレステ
ロールについては１ヶ月間効果が継続したが、２ヶ月後
には効果が消失し、投与前と同じ値になった。When the administration was stopped, the effects of total cholesterol and HDL-cholesterol continued for 1 month, but the effects disappeared after 2 months, and the values were the same as before the administration.
第１図は本発明の第１実施例の薬効を示すグラフ、第２
図は本発明の第２実施例の薬効を示すグラフ、第３図は
本発明の第３実施例の薬効を示すグラフである。FIG. 1 is a graph showing the drug efficacy of the first embodiment of the present invention,
FIG. 3 is a graph showing the drug efficacy of the second embodiment of the present invention, and FIG. 3 is a graph showing the drug efficacy of the third embodiment of the present invention.
Claims (1)
とする脂質代謝改善剤。1. A lipid metabolism improving agent comprising 4'-galactosyl lactose as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6895388A JPH0621074B2 (en) | 1988-03-23 | 1988-03-23 | Lipid metabolism improver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6895388A JPH0621074B2 (en) | 1988-03-23 | 1988-03-23 | Lipid metabolism improver |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01242529A JPH01242529A (en) | 1989-09-27 |
| JPH0621074B2 true JPH0621074B2 (en) | 1994-03-23 |
Family
ID=13388544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6895388A Expired - Lifetime JPH0621074B2 (en) | 1988-03-23 | 1988-03-23 | Lipid metabolism improver |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0621074B2 (en) |
-
1988
- 1988-03-23 JP JP6895388A patent/JPH0621074B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH01242529A (en) | 1989-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5690261B2 (en) | Compositions and uses comprising β-hydroxy-β-methylbutyric acid and at least one amino acid | |
| JP5574561B2 (en) | Total enteral nutrition composition | |
| MADSEN et al. | Hypophysectomy for diabetic angiopathy: a controlled clinical trial | |
| JP5798648B2 (en) | Anti-fatigue agent containing amino acid composition | |
| US20030190369A1 (en) | Vitamin formulation for enhancing bone strength | |
| Samuel et al. | Effect of neomycin on serum cholesterol level of man. | |
| JPH0651626B2 (en) | Composition for treating tissue degenerative inflammatory disease | |
| JP2008534599A (en) | Amino acid-containing composition for preventing or improving decrease in skeletal muscle mass in the elderly | |
| RU2001110097A (en) | THERAPEUTIC COMPOSITIONS (II) | |
| JPH0716076A (en) | Preparations for smokers | |
| Tabor et al. | Corneal damage due to eye contact with chlorhexidine gluconate | |
| WO2008065457A2 (en) | Herbal mixture with fraxinus, achillea and melissa to improve metabolism, boost immunity and help in therapy | |
| AU6485499A (en) | Preparation and use of solidified oils | |
| Perrino | Diabetes and periodontal disease: an example of an oral/systemic relationship | |
| EP0391218B1 (en) | Agent for the atopy prophylaxis | |
| Beling et al. | Long-term experience with indapamide | |
| RU2169593C2 (en) | Method for preventing and treating vascular complications of diabetes mellitus | |
| JP3871262B2 (en) | Liquid nutrition composition | |
| JPH06192104A (en) | Composition for curing and preventing infantile dysbolism | |
| US20060275505A1 (en) | Method and composition for increasing the alkalinity of the body | |
| August et al. | Calcitonin therapy of children with osteogenesis imperfecta | |
| Botter | A clinical double-blind comparison of maprotiline and amitriptvline in depression | |
| JPH01242529A (en) | Lipid metabolism improving agent | |
| JP2000302677A (en) | Medicine and food/feed composition having improving action on carnitine self production ability | |
| Soskin et al. | Medical treatment of hyperthyroidism with a high fat diet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |